Timmune
In 2015, Beike founded Timmune to develop what now comprises of cell therapies and fusion protein molecule drugs based on proprietary MAR and TriTE technology.
ALT-803
In 2014, Beike Biotechnology signed an exclusive China licensing agreement with Altor Bioscience to develop and commercialize ALT-803 in China.
| Product | Discovery | IND Enabling | Phase 1 | Phase 2 | Phase 3 | BLA | In cooperation with |
|---|---|---|---|---|---|---|---|
| CAR-T/CD19 with TriTE construct |
|
||||||
| MAR-T/GP100 with TriTE construct |
|
||||||
| MAR-T/WT1 with TriTE construct |
|
||||||
| MAR-T/ESO1 with TriTE construct |
|
||||||
| MAR-TriTE/CD19 |
|
||||||
| MAR-TriTE/WT1 |
|
||||||
| MAR-TriTE/ESO1 |
|
||||||
| ALT-803 | NMI Bladder Cancer |
|